Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Viracta Therapeutics Q3 2024 GAAP EPS $(0.27) Misses $(0.24) Estimate, Cash, Cash Equivalents, And Short-term Investments Of Approximately $21.1M Is Expected To Fund Operations Late Into The First Quarter Of 2025

Author: Benzinga Newsdesk | November 13, 2024 07:26am
Viracta Therapeutics (NASDAQ:VIRX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.24) by 12.5 percent.

Posted In: VIRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist